NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting
Data confirm bactericidal activity of NB-003 against P. acnes, suggest promise of nanoemulsions in topical acne therapy
ANN ARBOR, Mich.--(BUSINESS WIRE)--Jul 29, 2009 - NanoBio Corp. today announced that it will present compelling new data for NB-003, the company's nanoemulsion based clinical stage product for the treatment of acne. The information will be delivered orally and in poster format at the Academy of Dermatology Summer Meeting, taking place July 29-August 2nd at the Hynes Convention Center, Boston, Mass. Posters will be available for download during the meeting and from the NanoBio web site. The oral presentation schedule is as follows:
Poster Presentation # 106 - Thursday, July 30, 10:00 AM
Poster Presentation # 109 - Thursday, July 30, 10:30 AM
NB-003 uniquely penetrates the skin and enters epidermal tissues targeting the oil producing glands connected to a hair follicle. This penetration results in effective delivery of the nanoemulsion droplets to the site of infection. These droplets disrupt the P. acnes and are cidal on contact. NB-003 and other NanoBio dermatological products are derived from NanoBio's patented NanoStat™ technology platform. NanoBio is currently conducting a Phase I study with NB-003.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Contact: John Coffey, 734-302-9107
Vice President, Business Development
Andrea tenBroek / Laura Coluci
Posted: July 2009